Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMelatoninMelatonin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Oral Melatonin in Critically Ill Patients with COVID-19: A quasi-experimental pragmatic trial

Sánchez-García et al., Authorea Inc., doi:10.22541/au.175308854.41780414/v1, Jul 2025
https://c19early.org/sanchezgarcia2.html
Mortality 42% Improvement Relative Risk Melatonin  Sánchez-García et al.  ICU PATIENTS Is very late treatment with melatonin beneficial for COVID-19? Prospective study of 335 patients in Spain Lower mortality with melatonin (p=0.0025) c19early.org Sánchez-García et al., Authorea Inc., Jul 2025 Favorsmelatonin Favorscontrol 0 0.5 1 1.5 2+
Melatonin for COVID-19
11th treatment shown to reduce risk in December 2020, now with p = 0.000000011 from 20 studies.
Lower risk for mortality, ventilation, and recovery.
No treatment is 100% effective. Protocols combine treatments.
6,000+ studies for 175 treatments. c19early.org
Quasi-experimental trial of 335 critically ill COVID-19 patients showing significantly lower 90-day mortality with high-dose oral bedtime melatonin (50-200 mg). The study alternated between control and treatment periods, with 202 patients receiving melatonin and 133 receiving standard care. Melatonin-treated patients had lower SOFA scores at day 4 and beyond. The alternating time-period design introduces potential confounding over time based on variants or changes in SOC. Some supplementary analysis and tables noted in the paper are not currently available.
risk of death, 41.9% lower, RR 0.58, p = 0.002, treatment 42 of 202 (20.8%), control 48 of 133 (36.1%), NNT 6.5, odds ratio converted to relative risk, day 90.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sánchez-García et al., 21 Jul 2025, prospective, Spain, preprint, 23 authors.
Oral Melatonin in Critically Ill Patients with COVID-19: A quasi-experimental pragmatic trial.
Miguel Sánchez-García, Jesús A F Tresguerres, Manuel Álvarez-González, Belén De La Hera, Virginia Puebla, Lidia Ybañez, José-Manuel Martínez-Sesmero, Antonio Blesa, Juan-Carlos Martín-Benítez, Fernando Martínez-Sagasti, Paloma González-Arenas, Sara Domingo, Cándido Pardo, Silmary Maichle, Carolina Postigo, Sara De-Miguel, María Bringas, Raquel González-Casanova, Viktor Yordanov, Alberto Delgado-Iribarren, Esther Culebras, Miguel A. Armengol-De La-Hoz, Antonio Núñez-Reiz
doi:10.22541/au.175308854.41780414/v1
Melatonin has demonstrated antioxidant, anti-inflammatory, and potential antiviral properties. Its therapeutic role in critically ill COVID-19 patients admitted to intensive care was underexplored at the start of the pandemic. We conducted a quasiexperimental, pragmatic study over 4 consecutive uninterrupted time periods alternating control groups receiving standard of care (SoC) with treatment groups receiving SoC plus high-dose oral bedtime melatonin (50-200 mg) (OBM). The primary endpoint was 90-day mortality; secondary outcomes included sequential organ failure assessment (SOFA) scores at 4, 7, 14 and 30 days and pre-defined severe adverse events (SAEs). A total of 335 of 339 consecutive patients with a predicted stay >48 hours were enrolled; 202 received OBM with SoC and 133 received SoC alone. OBM was dispensed during the second (n=162) and fourth (n=40) study periods after the first (n=40) and third (n=93) control group periods, respectively. Melatonin therapy was associated with significantly lower 90-day mortality (20.8% vs 36.1%, OR 0.46, 95% CI 0.28-0.76). Subjects receiving melatonin had lower SOFA scores on day 4 and subsequent study visits. SAEs occurred in 84 (41.6%) subjects on OBM and in 80 (60.2%) receiving SoC (risk ratio 0.68, 95% CI 0.54-0.87; p=0.001). High-dose oral melatonin was safe and associated with improved clinical outcomes. Further evaluation of melatonin and its potential antiviral effects in future epidemics is warranted.
Hosted file Figure_3_a-b-c.docx available at https://authorea.com/users/947350/articles/1317214-oral- melatonin-in-critically-ill-patients-with-covid-19-a-quasi-experimental-pragmatic-trial Hosted file Table_1.docx available at https://authorea.com/users/947350/articles/1317214-oral-melatonin- in-critically-ill-patients-with-covid-19-a-quasi-experimental-pragmatic-trial Hosted file Table_2.docx available at https://authorea.com/users/947350/articles/1317214-oral-melatonin- in-critically-ill-patients-with-covid-19-a-quasi-experimental-pragmatic-trial
DOI record: { "DOI": "10.22541/au.175308854.41780414/v1", "URL": "http://dx.doi.org/10.22541/au.175308854.41780414/v1", "accepted": { "date-parts": [ [ 2025, 7, 21 ] ] }, "author": [ { "ORCID": "https://orcid.org/0000-0002-8775-255X", "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "authenticated-orcid": true, "family": "Sánchez-García", "given": "Miguel", "sequence": "first" }, { "affiliation": [ { "name": "Universidad Complutense de Madrid" } ], "family": "Tresguerres", "given": "Jesús A.F.", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Álvarez-González", "given": "Manuel", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Hera", "given": "Belén de la", "sequence": "additional" }, { "affiliation": [ { "name": "Hospital Clinico San Carlos" } ], "family": "Puebla", "given": "Virginia", "sequence": "additional" }, { "affiliation": [ { "name": "Hospital Clinico San Carlos" } ], "family": "Ybañez", "given": "Lidia", "sequence": "additional" }, { "affiliation": [ { "name": "Hospital Clinico San Carlos" } ], "family": "Martínez-Sesmero", "given": "José-Manuel", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Blesa", "given": "Antonio", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Martín-Benítez", "given": "Juan-Carlos", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Martínez-Sagasti", "given": "Fernando", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "González-Arenas", "given": "Paloma", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Domingo", "given": "Sara", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Pardo", "given": "Cándido", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Maichle", "given": "Silmary", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Postigo", "given": "Carolina", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "De-Miguel", "given": "Sara", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Bringas", "given": "María", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "González-Casanova", "given": "Raquel", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Yordanov", "given": "Viktor", "sequence": "additional" }, { "affiliation": [ { "name": "Hospital Clinico San Carlos" } ], "family": "Delgado-Iribarren", "given": "Alberto", "sequence": "additional" }, { "affiliation": [ { "name": "Hospital Clinico San Carlos" } ], "family": "Culebras", "given": "Esther", "sequence": "additional" }, { "affiliation": [ { "name": "Junta de Andalucia Servicio Andaluz de Salud" } ], "family": "la-Hoz", "given": "Miguel A. Armengol-de", "sequence": "additional" }, { "affiliation": [ { "name": "Instituto de Investigacion Sanitaria Hospital Clinico San Carlos" } ], "family": "Núñez-Reiz", "given": "Antonio", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 7, 21 ] ], "date-time": "2025-07-21T09:02:29Z", "timestamp": 1753088549000 }, "deposited": { "date-parts": [ [ 2025, 7, 21 ] ], "date-time": "2025-07-21T09:02:29Z", "timestamp": 1753088549000 }, "group-title": "Preprints", "indexed": { "date-parts": [ [ 2025, 7, 21 ] ], "date-time": "2025-07-21T09:40:03Z", "timestamp": 1753090803905, "version": "3.41.2" }, "institution": [ { "name": "Authorea Inc." } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 7, 21 ] ] }, "member": "311", "original-title": [], "posted": { "date-parts": [ [ 2025, 7, 21 ] ] }, "prefix": "10.22541", "published": { "date-parts": [ [ 2025, 7, 21 ] ] }, "publisher": "Wiley", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://www.authorea.com/users/947350/articles/1317214-oral-melatonin-in-critically-ill-patients-with-covid-19-a-quasi-experimental-pragmatic-trial?commit=ccf5e26c648ceb31a81a6409ae518a0b16155058" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "subtype": "preprint", "title": "Oral Melatonin in Critically Ill Patients with COVID-19: A quasi-experimental pragmatic trial.", "type": "posted-content" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit